Fight Aging! Newsletter, September 14th 2026
Key claim: Fight Aging! argues that cheap aging interventions face a structural mismatch with expensive clinical-trial pathways, presents the adaptive cost hypothesis as a viewpoint on antagonistic pleiotropy, and covers semaglutide in a longevity frame.
Abstract
Fight Aging! publishes news and commentary relevant to the goal of ending all age-related disease, to be achieved by bringing the mechanisms of aging under the control of modern medicine. This weekly newsletter is sent to thousands of interested subscribers. To subscribe to the newsletter, please visit: https://www.fightaging.org/newsletter/. To unsubscribe, send email or reply to this email at newsletter@fightaging.org with “unsubscribe” in the subject or body. Longevity Industry Consulting Services Reason, the founder of Fight Aging! and Repair Biotechnologies, offers strategic consulting services to investors, entrepreneurs, and others interested in the longevity industry and its complexities. To find out more: https://www.fightaging.org/services/ Contents The Challenge of Cheap Interventions and Expensive Clinical Trials The Adaptive Cost Hypothesis of Aging, a Viewpoint on Antagonist Pleiotropy Semaglutide to Reduce […]
Why this matters
Fight Aging! argues that cheap aging interventions face a structural mismatch with expensive clinical-trial pathways, presents the adaptive cost hypothesis as a viewpoint on antagonistic pleiotropy, and covers semaglutide in a longevity frame.